Technical Analysis for HARP - Harpoon Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 16.24 0.62% 0.10
HARP closed up 0.62 percent on Friday, July 10, 2020, on 26 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical HARP trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 0.62%
Oversold Stochastic Weakness 0.62%
Outside Day Range Expansion -2.75%
Narrow Range Bar Range Contraction -1.93%
NR7 Range Contraction -1.93%
Lower Bollinger Band Walk Weakness -1.93%
Stochastic Reached Oversold Weakness -1.93%
Inside Day Range Contraction -1.93%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Medicine Cancer Medical Specialties Diseases Oncology Immunotherapy Prostate Cancer Cancer Immunotherapy Ovarian Cancer Multiple Myeloma Tumors Proteins Treatment Of Ovarian Cancer Metastatic Castration Resistant Prostate Cancer Neuvenge Small Cell Lung Cancer

Is HARP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.02
52 Week Low 10.27
Average Volume 202,163
200-Day Moving Average 14.99
50-Day Moving Average 17.08
20-Day Moving Average 17.31
10-Day Moving Average 16.63
Average True Range 1.12
ADX 11.9
+DI 14.74
-DI 18.77
Chandelier Exit (Long, 3 ATRs ) 15.91
Chandelier Exit (Short, 3 ATRs ) 19.28
Upper Bollinger Band 18.79
Lower Bollinger Band 15.82
Percent B (%b) 0.14
BandWidth 17.16
MACD Line -0.31
MACD Signal Line -0.12
MACD Histogram -0.1897
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.10
Resistance 3 (R3) 17.12 16.85 16.95
Resistance 2 (R2) 16.85 16.64 16.84 16.90
Resistance 1 (R1) 16.55 16.50 16.42 16.53 16.86
Pivot Point 16.28 16.28 16.22 16.27 16.28
Support 1 (S1) 15.98 16.07 15.85 15.96 15.62
Support 2 (S2) 15.71 15.93 15.70 15.58
Support 3 (S3) 15.41 15.71 15.53
Support 4 (S4) 15.39